Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL positive |
| Therapy | Dubermatinib + Olaparib |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | head and neck squamous cell carcinoma | sensitive | Dubermatinib + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a head and neck squamous cell carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). | 27671334 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27671334) | AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. | Full reference... |